


REMARKS

The claims are 1-6, 8-14, and 16-21, with claims 1, 16, 18 and 21 being independent. Claims 7 and 15 have been cancelled without prejudice or disclaimer. Claims 1, 3-6, 8-14 and 16-20 have been amended to recite the specific insulin sensitiser, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and/or to remove multiple claim dependencies or to change the claim dependency. Support for the amendment may be found in original claim 7 and in the specification at page 4, line 33 to page 5, line 16. No new matter has been added.

Favorable consideration and early passage to issue are respectfully requested.

Respectfully submitted,



Kathryn E. Sieburth
Attorney for Applicants
Registration No. 40,072

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5012
Facsimile: (610) 270-5090
N:\kls\cases\p32185c1\p32185C1 Preliminary Amendment.doc